EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Bowel Obstruction/Ileus Associated With the Use of Glucagon‐Like Peptide‐1 Receptor Agonists: A Nationwide Database Study

Yuichiro Matsuo iD, Akira Okada iD, Takashi Sakamoto, Hideo Yasunaga

Diabetes, Obesity and Metabolism · 2026

DOI: 10.1111/dom.71189 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, 2026. Verfasst von Yuichiro Matsuo und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Epidemiology and Health Economics, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan. Hauptthemen laut MEDLINE: Glucagon-Like Peptide-1 Receptor Agonists, Diabetes Mellitus, Type 2, Intestinal Obstruction, Ileus. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Ministry of Health, Labour and Welfare.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

The association between glucagon‐like peptide‐1 receptor agonist (GLP‐1RA) use and the development of bowel obstruction/ileus remains unclear, and evidence for specific bowel obstruction/ileus subtypes remains limited. We examined the association between GLP‐1RA use and the incidence of bowel obstruction/ileus subtypes across different subgroups of individuals.

Methods

Using the commercially available Japanese administrative claims DeSC database, we identified individuals aged ≥ 18 years with type 2 diabetes who newly initiated either GLP‐1RAs or sodium‐glucose cotransporter 2 inhibitors (SGLT2is) between April 2016 and February 2024. An active‐comparator new‐user design was adopted, designating GLP‐1RA users as the exposure group and SGLT2i users as the control group. The primary outcome was bowel obstruction/ileus requiring tube decompression or surgery within 1 year. Secondary outcomes included specified small bowel obstruction, small bowel obstruction requiring surgery, paralytic ileus and colonic volvulus. Inverse probability weighting with propensity scores was used to adjust for confounding. Adjusted cumulative incidence was estimated using Kaplan–Meier methods; hazard ratios were estimated using Cox regression.

Results

Among 298 124 eligible individuals, 25 779 and 272 345 were classified into the GLP‐1RA and SGLT2i groups, respectively. The adjusted 1‐year incidence proportion of the primary outcome did not significantly differ between groups (0.14% vs. 0.17%; difference −0.03%, 95% confidence interval (CI), −0.10% to 0.04%; hazard ratio 0.80, 95% CI, 0.52–1.24). No significant between‐group differences were observed for the secondary outcomes.

Conclusions

GLP‐1RA initiation in individuals with type 2 diabetes was not associated with an increased risk of bowel obstruction/ileus compared with SGLT2i initiation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glucagon-Like Peptide-1 Receptor AgonistsDiabetes Mellitus, Type 2Intestinal ObstructionIleusHypoglycemic AgentsHumansFemaleMaleDatabases, FactualMiddle AgedAgedIncidenceJapanSodium-Glucose Transporter 2 InhibitorsAdult

Stichwörter der Autor:innen

GLP‐1 analogueSGLT2 inhibitorantidiabetic drugcohort studydatabase researchpharmaco‐epidemiology

Substanzen

Glucagon-Like Peptide-1 Receptor AgonistsSodium-Glucose Transporter 2 InhibitorsHypoglycemic Agents

Autor:innen und Institutionen

  • Department of Clinical Epidemiology and Health Economics, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan.
  • Department of Prevention of Diabetes and Lifestyle-Related Diseases, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan.
  • Gastroenterology Center, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Koto-ku, Tokyo, Japan.
  • Department of Healthcare Quality Assessment, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan.

ORCID-Profile: Yuichiro Matsuo, Akira Okada

Förderung

  • Ministry of Health, Labour and Welfare

Zitieren

APA

Matsuo, Y., Okada, A., Sakamoto, T., & Yasunaga, H. (2026). Bowel Obstruction/Ileus Associated With the Use of Glucagon‐Like Peptide‐1 Receptor Agonists: A Nationwide Database Study. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.71189

Vancouver

Matsuo Y, Okada A, Sakamoto T, Yasunaga H. Bowel Obstruction/Ileus Associated With the Use of Glucagon‐Like Peptide‐1 Receptor Agonists: A Nationwide Database Study. Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.71189

BibTeX
@article{Matsuo2026,
  author = {Matsuo, Yuichiro and Okada, Akira and Sakamoto, Takashi and Yasunaga, Hideo},
  title = {Bowel Obstruction/Ileus Associated With the Use of Glucagon‐Like Peptide‐1 Receptor Agonists: A Nationwide Database Study},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2026},
  doi = {10.1111/dom.71189}
}
Kostenlos starten →